Speaker Innovation for Health 2023

Erik Manting | CEO, Mendus

Erik Manting holds a MSc in Medical Biology and a PhD in Molecular Microbiology. He worked for a number of years as a post-doctoral researcher in the field of immunology before making a career switch to banking in 2001. He spent more than 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co.

Erik became CEO of DCPrime BV in 2018 and CEO of Immunicum AB in March 2021, following the merger between both companies. The combined company was renamed Mendus in June 2022. Mendus AB (publ) is a clinical-stage biotechnology company focusing on immunotherapies addressing tumor recurrence, with headquarters in Stockholm, Sweden and R&D facilities in Leiden, The Netherlands.

ABOUT MENDUS AB (PUBL)

ABOUT MENDUS AB (PUBL) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Powered by:
Hyphen Projects

Let's connect:

Book a ticket

FAQ
Contact Us
Privacy Policy
Terms & Conditions
Chamber of Commerce: 32110979
VAT no: NL8184.34.491.B01

Keep me informed Download our event app

© Copyright 2023 by Hyphen Projects